TolerogenixX GmbH

TolerogenixX GmbH TolerogenixX verfügt über eine patentierte Technologie, mit der unerwünschte Abwehrreaktionen de

11/03/2026
Spannende Vorträge heute an der Uniklinik Heidelberg zum Thema Nierentransplantation.Von neuen Operationstechniken bis h...
04/05/2024

Spannende Vorträge heute an der Uniklinik Heidelberg zum Thema Nierentransplantation.
Von neuen Operationstechniken bis hin zu zelltherapeutischen Verfahren gab es viele Neuigkeiten für die vielen Zuhörer.

Exciting days at the Cell and Gene Conference on the Med are coming to an end. It is impressive to see what is happening...
11/04/2024

Exciting days at the Cell and Gene Conference on the Med are coming to an end. It is impressive to see what is happening in the field and that more and more approaches are reaching patients and leading to previously unimagined treatment successes. Many thanks for the great interest in MIC therapy and the numerous enriching discussions.
, , , ,

Today is World Kidney Day.Chronic kidney failure is still a heavy burden for those affected.TolerogenixX is fighting to ...
14/03/2024

Today is World Kidney Day.
Chronic kidney failure is still a heavy burden for those affected.
TolerogenixX is fighting to improve the lives of kidney transplant patients with its MIC cell therapy.
A phase IIB study is currently running.

We are thrilled to be able to report 3 extremely positive updates at the same time:X Ongoing Phase IIb study is being ex...
06/07/2023

We are thrilled to be able to report 3 extremely positive updates at the same time:

X Ongoing Phase IIb study is being expanded to the minimal concomitant immunosuppression treatment arm.
X 5-year results of Phase I study confirm efficacy and safety of MIC cell therapy in living kidney transplantation.
X Completion of series A round of about 12 million Euros.

For more information, please see our press release.

— 5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantation

03/11/2022

Today we presented a putative in vivo mechanism how MIC treatment inhibits progression of active nephritis by the destruction of tertiary lymphoid…

02/10/2022

Publication in high-impact Journal of the American Society of NephrologyResults pave the way for a novel cell therapy in organ transplantation ...

09/04/2022

— Study of MIC-Lx cell treatment, a potentially curative approach to achieve sustained immune tolerance in transplanted and autoimmune patients as shown in previous Phase Ib study

Adresse

Im Neuenheimer Feld 162
Heidelberg
69120

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von TolerogenixX GmbH erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Teilen